Aspreva Announces Preliminary Revenues for First Quarter 2007

    VICTORIA, April 18 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals
 Corporation ( ASPV; TSX: ASV) today announced preliminary and
 unaudited net revenues of approximately US$59 million for the first quarter
 of 2007.
     As previously announced, Aspreva will release its full financial
 results on Wednesday, May 2, 2007. The Company will hold a conference call
 and webcast beginning at 5:00 p.m. EDT (2:00 p.m. PDT) to discuss results
 and to provide a general corporate update.
     About Aspreva Pharmaceuticals
     Aspreva is a global pharmaceutical company focused on identifying,
 developing, and, upon approval, commercializing evidence-based medicines
 for patients living with less common diseases. Aspreva common stock is
 traded on the NASDAQ Global Select Market under the trading symbol "ASPV"
 and on the Toronto Stock Exchange under the trading symbol "ASV".
     Conference Call
     Aspreva will host a conference call to discuss results for the first
 quarter 2007 on Wednesday, May 2, 2007 at 5:00 p.m. EDT (2:00 p.m. PDT).
     Dial-in information:
     North America (toll free): 1-800-510-9661
     International: 1-617-614-3452
     Enter passcode: 21957711
     The call will be available for replay until Wednesday, May 9th, by
 calling 1-888-286-8010 (North America) or 1-617-801-6888 (International)
 and entering the pass code 16213778.
     A live webcast will also be available to all interested parties on
 Aspreva's website: www.aspreva.com. Please click on the "Webcasts and
 Events" link under the Investors section of Aspreva's website. A replay of
 the webcast will be available until the Company's second quarter 2007
 conference call.
     The revenue figures in this press release are preliminary and unaudited
 and are not a complete disclosure of our quarterly financial results.
 Unless otherwise specified, all amounts are in U.S. dollars and are
 reported under U.S. GAAP.
     This news release contains forward-looking statements within the
 meaning of the United States Private Securities Litigation Reform Act of
 1995 and forward-looking information within the meaning of applicable
 securities laws in Canada (collectively, "forward-looking statements"). The
 words "anticipates", "believes", "budgets", "could", "estimates",
 "expects", "forecasts", "intends", "may", "might", "plans", "projects",
 "schedule", "should", "will", "would" and similar expressions are often
 intended to identify forward-looking statements, although not all
 forward-looking statements contain these identifying words. The
 forward-looking statements in this news release include, but are not
 limited to, statements concerning our strategy, future operations, clinical
 trials, and prospects and plans of management.
     Various estimates and assumptions were used in drawing the conclusions
 or making the forecasts and projections contained in the forward-looking
 statements in this news release. Certain risks, uncertainties and factors
 are taken into account as part of our assumptions underlying the
 forward-looking statements, including: our ability to successfully conduct
 our clinical trials and studies; difficulties or delays in the progress,
 timing and results of clinical trials and studies; difficulties or delays
 in obtaining regulatory approvals; we may not be able to develop and obtain
 regulatory approval for some of the products in our targeted indications;
 our ability to succeed at establishing a successful commercialization
 program for any of our products; the risk that we may not sustain our
 profitability; our ability to attract and retain collaborations relating to
 the development and commercialization of new indications; competition from
 other pharmaceutical or biotechnology companies; our ability to raise
 additional financing required to fund further research and development,
 clinical studies, and obtain regulatory approvals, on commercially
 acceptable terms or at all; economic and capital market conditions; our
 ability to obtain and protect patents and other intellectual property
 rights; our ability to operate without infringing the intellectual property
 rights of others; our ability to comply with applicable governmental
 regulations and standards; currency exchange rates; and our ability to
 successfully attract and retain skilled and experienced personnel.
     Although we have attempted to identify the important risks,
 uncertainties and other factors that could cause actual results or events
 to differ materially from those expressed or implied in the forward-looking
 statements, there may be other factors that cause actual results or events
 to differ from those expressed or implied in the forward-looking
 statements. For a more thorough discussion of the risks associated with our
 business, see the "Risk Factors" section in the Company's Annual Report on
 Form 10-K for the year ended December 31, 2006 filed with the U.S.
 Securities Exchange Commission on EDGAR at www.sec.gov and on SEDAR at
 www.sedar.com. All forward-looking statements are qualified in their
 entirety by this cautionary statement and Aspreva undertakes no obligation
 to revise or update any forward-looking statements as a result of new
 information, future events or otherwise after the date hereof.
     CONTACT: Sage Baker, VP, Investor Relations & Corporate Communications,
 Aspreva Pharmaceuticals, (250) 744-2488 ext. 84270, sbaker@aspreva.com
 
 

SOURCE Aspreva Pharmaceuticals